Seres Therapeutics, Inc. (Nasdaq:MCRB), a leading microbiome therapeutics company, has announced that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridium difficile infection (CDI), in the United States (US) and Canada. If approved, SER-109 would become the first ever FDA approved microbiome therapeutic.
Latham & Watkins LLP represents Seres Therapeutics, Inc. in the license agreement with a team led by Bay Area partner Judith Hasko, with Bay Area associate Peggy Ni and New York associate Jiqiang Lin. Corporate aspects of the transaction were led by Boston/New York partner Peter Handrinos, with London/Boston associate Nicole McNeil and Boston associate Jennifer Yoon.
Advice was also provided on tax matters by Bay Area partner Kirt Switzer, with Bay Area associates Jessica Chen and Derek Gumm; and on intellectual property matters by Washington, D.C. partner Jeremiah Wolsk.